|
|
Volumn 322, Issue 5899, 2008, Pages 210-213
|
|
Spiraling costs threaten gridlock
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PLACEBO;
CARDIOVASCULAR DISEASE;
DATABASE;
DISEASE TREATMENT;
ECONOMETRICS;
HEALTH EXPENDITURE;
HEALTH SERVICES;
HEALTH WORKER;
RESEARCH WORK;
WILLINGNESS TO PAY;
CLINICAL RESEARCH;
CLINICAL TRIAL;
COST;
DRUG INDUSTRY;
DRUG RESEARCH;
FOOD AND DRUG ADMINISTRATION;
GOLD STANDARD;
GOVERNMENT;
HUMAN;
MEDICAL RESEARCH;
OUTCOMES RESEARCH;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
UNITED STATES;
CLINICAL PROTOCOL;
DRUG APPROVAL;
ECONOMICS;
NOTE;
PATIENT SELECTION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
CLINICAL PROTOCOLS;
CLINICAL TRIALS, PHASE I AS TOPIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
CLINICAL TRIALS, PHASE III AS TOPIC;
COSTS AND COST ANALYSIS;
DRUG APPROVAL;
HUMANS;
PATIENT SELECTION;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
UNITED STATES;
|
|
EID: 53749085376
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.322.5899.210 Document Type: Short Survey |
|
Times cited : (39)
|
|
References (0)
|
